Effect of Add-on SGLT2i, TZD, or Combination Therapy in Type 2 Diabetes Patients on DPP4 Inhibitors

A phase 4 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 100 participants.

Also called NCT07108985

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 100 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07108985
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT07108985. Randomized; no masking; primary purpose treatment. Start 2025-09 (anticipated); primary completion 2029-09-01 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Effect of Add-on SGLT2i, TZD, or Combination Therapy in Type 2 Diabetes Patients on DPP4 Inhibitors
Condition
Diabetes Mellitus, Type 2
Condition
Hyperglycemia
Intervention (Drug)
Sitagliptin 100 mg
Intervention (Drug)
Sitagliptin 100 mg + Dapagliflozin 10 mg
Intervention (Drug)
Sitagliptin 100 mg + Dapagliflozin 10 mg
Intervention (Drug)
Sitagliptin 100 mg + Dapagliflozin 10 mg + Lobeglitazone 0.5 mg
Lead sponsor
Yonsei University (class: other)

Record details

Record id
cardio:ct-nct07108985
Content hash
da6a9b45cf8541d0d633ba6d7f45d3493c52629e3b5fef5818b16871d5ebb5a6